Rituximab in paediatric onset multiple sclerosis: a case series.
Salzer J, Lycke J, Wickström R, Naver H, Piehl F, Svenningsson A
J. Neurol. 2016 Feb;263(2):322-326

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, et al
Neurology 2016 Nov;87(20):2074-2081

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, et al
Ann. Neurol. 2016 Jun;79(6):950-8

Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS.
de Flon P, Laurell K, Söderström L, Gunnarsson M, Svenningsson A
Mult. Scler. 2017 Aug;23(9):1249-1257

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T, et al
Neurology 2016 Jul;87(2):141-7

Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, et al
Mult. Scler. 2017 Jul;():1352458517720044